# Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

> **NCT06427226** · PHASE2 · RECRUITING · sponsor: **Tanta University** · enrollment: 46 (estimated)

## Conditions studied

- Doxorubicin Induced Cardiomyopathy
- Breast Cancer

## Interventions

- **DRUG:** Dapagliflozin 10mg Tab

## Key facts

- **NCT ID:** NCT06427226
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06427226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06427226, "Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06427226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*